Astria Therapeutics (NASDAQ:ATXS) Trading Up 5.5% – Still a Buy?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price shot up 5.5% on Wednesday . The company traded as high as $10.73 and last traded at $10.72. 431,898 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 594,279 shares. The stock had previously closed at $10.16.

Analysts Set New Price Targets

Several research firms recently commented on ATXS. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Price Performance

The stock has a market capitalization of $585.18 million, a PE ratio of -4.96 and a beta of 0.67. The business’s fifty day moving average price is $10.92 and its two-hundred day moving average price is $10.68.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. FMR LLC boosted its position in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP lifted its stake in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of Astria Therapeutics in the 2nd quarter valued at $6,142,000. Redmile Group LLC acquired a new stake in shares of Astria Therapeutics in the third quarter worth $3,423,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Astria Therapeutics during the second quarter worth $2,561,000. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.